Drugs Made In America Acquisition Corp.

Drugs Made In America Acquisition Corp. (DMAA) filed an amended registration statement on Form S-1/A with the SEC on January 6, 2025, advancing its effort to complete an initial public offering on Nasdaq. The blank-check company is focused on the domestic pharmaceutical manufacturing sector, targeting acquisition opportunities aligned with the U.S. drug-production reshoring theme. As of the filing date, the SPAC was in pre-IPO registration; sponsor details are disclosed within the underlying filing documents. To access complete filing timelines, sponsor profiles, and real-time deal analytics on DMAA and the broader SPAC universe, sign up for full data at SpacDesk.